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Abstract 
Green routes, considering the use of plant extracts with high reducing power, have 
been investigated as alternative methods to obtain superparamagnetic cores for 
biomedical applications. Usually, these magnetic cores are further coated either with 
metal or non-metal materials. In particular, carbon-coated nanoparticles have several 
advantages in comparison to other coatings, since they usually offer higher chemical and 
thermal stability, larger surface area, biocompatibility and easier functionalization. In this 
research, different plant hydromethanolic extracts with high reducing power (i.e., Tamus 
communis L. shoots, Crateagus monogyna Jacq. flowers and Rubus ulmifolius Schott 
flowers) were investigated in the synthesis of magnetic cores for carbon-coated yolk-shell 
magnetic nanoparticles (CYSMNPs). Overall, the extract of Rubus ulmifolius has shown 
great ability to produce highly magnetic cores with more stability in distilled water. The 
nanocomposites were chemically functionalized with nitric acid to enhance the colloidal 
stability of the product synthesized. To set the best conditions for drug loading, different 
working solutions (i.e., phosphate buffer solutions (PBS) pH 6.0, pH 7.4 and pH 8.0) were 
investigated. It is known that there are differences between the pH of the normal tissues 
(pH 7.4), the extracellular environment of the tumor (pH 6.5) and the endosome and 
lysosome (pH lower than 5.0). Then, according to the best loading, the drug release was 
also studied in different working solutions (i.e., PBS pH 4.5, PBS pH 6.0 and PBS pH 
7.4), to determine the efficiency of the synthesized material for drug delivery in cells 
targeted to cancer treatment. The results showed a drug release quantity 20% higher in 
acid environment than in neutral environment. However, this research demonstrates the 
outstanding ability to use the developed and optimized green CYSMNPs, as super-drug 
nanocarriers with great ability to load high content of the anticancer drug Doxorubicin. 
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Resumo 
As rotas verdes, considerando o uso de extratos de plantas com elevado poder 
redutor, foram investigadas como métodos alternativos para a obtenção de núcleos 
superparamagnéticos para aplicações biomédicas. Geralmente, esses núcleos magnéticos 
são revestidos com materiais metálicos ou não metálicos. Em particular, nanopartículas 
revestidas com materiais de carbono têm várias vantagens em comparação com outros 
revestimentos, uma vez que geralmente oferecem maior estabilidade química e térmica, 
maior área superficial, biocompatibilidade e facilidade de funcionalização. Neste 
trabalho, foram investigados diferentes extratos hidrometanólicos de plantas com alto 
poder redutor (i.e., brotos de Tamus communis L., flores de Crateagus monogyna Jacq e 
flores de Rubus ulmifolius Schott) na síntese de núcleos magnéticos para nanopartículas 
magnéticas do tipo “yolk-shell” revestidas com carbono (CYSMNPs). Em geral, o extrato 
de Rubus ulmifolius mostrou grande capacidade para produzir núcleos fortemente 
magnéticos e com maior estabilidade em água destilada. Os nanocompósitos foram 
funcionalizados quimicamente com ácido nítrico para aumentar a estabilidade coloidal do 
produto sintetizado. Para estabelecer as melhores condições para o carregamento do 
fármaco foram investigadas diferentes soluções de trabalho (i.e., PBS pH 6,0, PBS pH 
7,4, PBS pH 8,0). Sabe-se que há diferenças entre o pH dos tecidos normais (pH 7,4), o 
ambiente extracelular do tumor (pH 6,5) e o endossoma e lisossoma (pH menor que 5,0). 
Em seguida, a partir do melhor carregamento, foi estudada a liberação do fármaco 
também em diferentes soluções de trabalho (i.e., PBS pH 4,5, PBS pH 6,0, PBS pH 7,4), 
para determinar a eficiência do material sintetizado para administração de fármaco em 
células alvo para o tratamento de câncer. Os resultados mostraram que houve uma 
quantidade de liberação de fármaco 20% maior em ambiente ácido do que em ambiente 
neutro. No entanto, esta pesquisa demonstra a excelente capacidade de usar as CYSMNP 
ecológicas desenvolvidas e otimizadas, como nanotransportadores de com grande 
capacidade de carregar um elevado conteúdo do fármaco anticancerígeno Doxorrubicina.  
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1.1 Introduction 
Nanomaterials have been studied in the last decades for different applications. The 
search to synthesize materials with controlled shape and size, which can present 
specificity for some biomedical applications has united several areas, such as 
biomedicine, chemical, physics, engineering, biology and pharmaceutical 1. Among the 
applications are medical diagnosis and therapy, target drug delivery 2, magnetic resonance 
imaging (MRI) 3 and cancer hyperthermia treatment 1,4. Several methods to synthesize 
these nanomaterials have been developed with the desire to find some alternatives that 
are applicable, efficient and with minimal side effects. The methods of synthesis currently 
known are microemulsion, thermal decomposition, solvothermal, sonochemical, 
microwave-assisted, chemical vapor deposition, combustion synthesis, carbon arc, laser 
pyrolysis synthesis, co-precipitation and green routes 5,6. 
Green routes are alternative and environmentally friendly ways to synthesize 
magnetic nanoparticles (MNPs) 7,8. In this method, plant extracts are used to prepare the 
magnetic core and there are no harmful agents to be discarded. The plant extracts with 
high reducing power are able to promote the iron ions reduction and form oxides in a 
basic solution 6. The magnetic cores synthesized are coated with carbon in yolk-shell 
structures. The carbon-based coating, in relation to other coatings, shows better chemical 
and physical properties. Generally, these nanocomposites have high surface area, are 
chemically inert, are biocompatible, have thermal stability and electrical conductivity 9, 
which are desirable for biomedical applications. 
In addition to coating, the carbon-based yolk-shell magnetic nanoparticles 
(CYSMNPs) were functionalized with nitric acid to enhance the colloidal stability by the 
incorporation of carboxylic acid groups on the carbon-based shell. The functionalization 
leads to a dramatic change on the sample pHPZC values from highly basic to highly acid, 
before and after the treatment, respectively. The resultant CYSMNPs are negatively 
charged, enabling them to have great affinity with cationic drugs, such as Doxorubicin. 
The electronic affinity between both can be different in solutions with different pH. Such 
difference can facilitate both the drug loading and the drug release depending on the 
solution that will be used.  
However, due to this behavior, it is possible to study the optimization of the 
magnetic core production, coating and functionalization efficiency and the drug loading 
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and release environment, focusing on the release of higher amount of drug into acid 
environment (pH 4.5) simulating cancer cells and on the minimization of side effects in 
other cells, represented by slightly basic environment (pH 7.4). 
 
1.2 Objective 
The main objective of this thesis is the development and functionalization of 
intelligent magnetic nanostructures coated with carbon materials with high potential for 
the treatment of cancer through the controlled release of drugs. The magnetic core will be 
developed by a green route, where the biosynthesis of MNPs will be obtained by reduction 
of Fe (II) and Fe (III) using extracts of plants with high reducing power and ammonium 
hydroxide solution. This green methodology has already proven to have advantages over 
other chemical synthesis methodologies, namely in the obtention of more biocompatible 
NPs coated with biomolecules, such as polyphenols, which gives a more hydrophilic 
behavior and increases their colloidal stability, essential characteristics in biomedical 
applications 6,9. After the NPs synthesis and functionalization to provide the magnetic 
nanocomposites, the purpose will be to carry out controlled drug release tests, using 
Doxorubicin under different conditions, mainly altering the pH of the medium. Thus, 
controlling the pH of the medium, the drug would not exert side effects on normal  
cells 10,11.
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2.1 Magnetic nanoparticles 
At the beginning of the 21st century, there was an increase in the production and 
study of the nanometer-scale materials. The development and handling of these materials 
are studied in nanotechnology, the science that deals with structures between 1 and 100 
nanometers (nm). The nanoparticles (NPs) are structures that have nanometer scales equal 
to or less than 100 nm (1 nm = 10-9 m) 12,13. The Magnetic Nanoparticles (MNPs) started 
to be researched around the 1930s, when the concept of particles with magnetic domain 
was discussed by William Fuller Brown and Louis Néel. The meaning of the magnetic 
domain particles is that all the "spins" of the particle have the same direction when 
subjected to a magnetic field 14.  
The behavior of magnetic materials is classified based on their response to an 
external magnetic field. The description of magnetic field directions in the material helps 
to identify the different forms of magnetism. The three basic types of magnetism are 
diamagnetism, paramagnetism and ferromagnetism. The latter has two categories which 
are antiferromagnetism and ferrimagnetism 15–17. 
For pharmaceutical and medical applications, mainly in cancer therapy, the 
combination of magnetic nanoparticles with magnetic field is promising. Because with 
magnetic field it is possible to focus on the target cells, minimizing the side effects of the 
usual treatments, such as chemotherapy 18. The magnetic properties of these nanoparticles 
can be applied in magnetic resonance imaging (MRI) agents, hyperthermia agents 
(applying a high frequency magnetic field to selectively heat the NPs), or targeted drug 
delivery (a magnetic field gradient can direct magnetic vectors toward a given location 
for the drug release) 1–4,19. The main materials used for this purpose include metals or 
metal oxides, such as iron oxide nanoparticles 18. 
The main iron oxide nanoparticles are hematite (α-Fe2O3), magnetite (Fe3O4) and 
maghemite (γ-Fe2O4). NPs of those materials have been most investigated due to the 
diversity of possible applications. The superparamagnetic iron oxide nanoparticles 
(SPION) can be easily synthesized and generally are coated in the end of the process. The 
coating can make it viable to the desirable application reducing the potential of 
aggregation and avoiding the direct contact with the body. Moreover, the coating is very 
important to decrease the toxicity and improve the biocompatibility of these materials 3,17.  
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2.1.5 Nanocomposites 
Nanocomposites (NCs) are multi-phasic materials, whose matrix material 
incorporates units with dimension less than 100 nm. The properties of these material are 
a combination of the properties of both the matrix material and the nanosized filler. The 
interaction between a magnetic field gradient and the magnetic moments of the particles 
induces magnetomechanical forces, which can modify the format of the host materials or 
displace the material 20. 
According to Wen-jing Liu et al. (2014), the coatings of polymers, silica, carbon, 
or other materials over the magnetic particles can prevent aggregation, improve 
stabilization against degradation and functionalize the MNPs to extend their applications. 
The applications of nanocomposites are diverse, such as in magnetic separation, as 
catalyst supports, adsorbents, nanoheaters, lithium-ion batteries, supercapacitors and drug 
delivery agents 9,20. 
 
 
2.2 Methods of synthesis 
Several methods of MNPs synthesis have been studied in recent years, due to 
their potential applications. The choice of method depends on the different phases and the 
final desired compound. The most common nanoparticles are pure metals, such as Fe, Co 
and Ni; metallic oxides, like Fe3O4 and γ-Fe2O3; ferrites, like XFe2O4 (X can be Cu, Ni, 
Mn, Mg, among other metals); or alloys, such as FePt and CoPt. The main methods to 
synthesize MNPs are microemulsion, thermal decomposition, solvothermal, 
sonochemical, microwave-assisted, chemical vapor deposition, combustion synthesis, 
carbon arc, laser pyrolysis synthesis, co-precipitation and green routes 5. 
 
2.2.1 Microemulsion 
The water-in-oil (w/o) microemulsion is used to synthesize uniform sized MNPs, 
between 5 and 50 nm 5,21. In this method the MNPs are synthesized in reverse micelles, 
which are small reactors 21. Micelles are responsible for solubilization of organic 
compounds in water (oil-in-water, o/w) or hydrophilic compounds in the oil phase (w/o). 
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The surfactant has a hydrophobic tail and, due to that, it is a good emulsifier molecule 22. 
This system is isotropic and thermodynamically stable and consists in a two-phase system 
that contains three compounds: water, oil and surfactant (amphiphilic molecule). The 
surfactant molecule allows the formation of a transparent solution resulting from the 
reduction of interfacial tension between water and oil. Therefore, numerous drops of 
water will be distributed in the organic compound (oil) 5. 
The shape and size of the nanoparticles depend of the dimensions and shape of 
the water drop, which can be controlled by microemulsion method parameters. These 
parameters can be the type of surfactant and organic compound, the ratio 
surfactant/water/organic compound, the efficiency of surfactant for the size and shape of 
water drop desired, type and concentration of the reagents (salts and reducing agents), 
temperature, pH, method of mixture, mode and time of stirring 21. 
 
2.2.2 Thermal decomposition 
The high-temperature decomposition of organometallic precursors can result in 
the production of nanoparticles with size control and high level of monodispersity, 
between 5 and 11 nm. The homogeneous size is expected to contribute to a better 
controlled distribution of physical parameters 23. These organometallic compounds can 
be [Xn+(acac)n], where X is the metal (e.g., Fe, Mn, Co, Ni and Cr), with n equal to 2 or 
3, and acac is acetylacetonate; Xy(cup)y, in which cup is N-nitrosophenylhydroxylamine; 
or carbonyls such as Fe(CO)5. This synthesis uses organic solvents and surfactants like 
fatty acids, oleic acid and hexadecylamine 5. 
If the organometallic precursors have zerovalent metal in their composition, then 
they will initially produce metallic NPs, which could be oxidized, leading to high quality 
monodispersed metal oxides. Otherwise, decomposition of precursors with cationic metal 
centers (Mn+) leads directly to metal oxides NPs. The size and shape of MNPs will depend 
on reagents (starting reagents, organometallic compounds, surfactants and solvents), 
temperature and time of reaction 5,23. 
 
Chapter 2: State of the art 
 
10 
 
2.2.3 Hydrothermal and solvothermal routes 
The hydrothermal route is another alternative to synthesize MNPs. This reaction 
occurs in reactors or autoclaves in aqueous medium with high pressure and  
temperature 5. The method can be called solvothermal, to include all other solvents that 
can be used in the process 24. This method of MNPs Fe3O4 production uses an iron source 
(commonly, FeCl3.6H2O), a surfactant as a protective agent (polyethylene glycol – PEG; 
sodium dodecyl sulfate – SDS; ethylene glycol – EG) and an alkali source and 
electrostatic stabilizer (sodium acetate) 5,25,26.  
The solvothermal technique has high efficiency, however an important 
disadvantage is the slow reaction kinetics at any temperature. Microwave heating is 
sometimes used to increase the kinetics of crystallization 5. The diameter of the NPs of 
magnetite produced by the solvothermal method can be adjustable between 120-400 nm 
25. Furthermore, mixing of SDS and PEG results in smaller (15-190 nm) and more 
uniform NPs, but their size depends on reaction time, initial concentration of reagents, 
molar ratio of reagents, protective reagents, among other factors 26. 
 
2.2.4 Sonochemical 
The sonochemical process occurs due to the phenomena of acoustic cavitation. 
It is attractive because of its short time of reaction, and needs demanding conditions such 
as high local temperature (> 5000 K), pressure (> 20 MPa), and high cooling rates (> 
1010 K.s-1) 5,27. The acoustic cavitation consists in the formation, growth and implosive 
collapse of bubbles in liquids irradiated with high-intensity ultrasound 28. The implosive 
collapsing of the bubbles generate a short-lived localized hotspot through adiabatic 
compression or shock wave formation within the gas phase of the collapsing bubble 5,28. 
Kim et. al. (2005) 29 used reagents like FeCl3.6H2O, FeCl2.4H2O, C18H34O2, NH4OH and 
NaOH and they synthesized superparamagnetic iron oxide NPs with dimensions of 
approximately 15 nm. 
 
2.2.5 Microwave 
The microwave route is a fast, homogeneous and reproducible process to obtain 
iron oxide NPs, in which the concentration of the precursor, the time of irradiation and 
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the power are critical factors to the control of size. The sizes of the NPs obtained using 
this method generally are less than 10 nm 30. The advantages of this synthesis are the fast 
volumetric heating, high reaction rate, reduction of reaction time and the increase of the 
product yield (when compared with other conventional methods of heating), besides 
being more environmentally friendly 31. 
 
2.2.6 Chemical vapour deposition 
Chemical vapour deposition (CVD) can be defined as the deposition of a solid 
in a heated surface by chemical reaction in vapour phase. Processes such as thermal 
decomposition (pyrolysis), reduction, hydrolysis, disproportionation, oxidation, among 
other reactions, are necessary for the precipitation of solid products to occur in vapour 
phase 5,31. In this process, a carrier gas stream with precursors are feed continuously by a 
gas delivery system to a reaction chamber maintained under vacuum at high temperature 
(> 900 ºC). The reaction occurs in this chamber and the products combine to form clusters 
of NPs. The rapid expansion at the outlet of the reaction chamber causes growth and 
agglomeration of the particles 5. 
The CVD by the reaction of a halide employed to deposit iron oxide, commonly 
uses iron chloride III with water at 800-1000 ºC. The efficiency of this method depends 
on the low concentration of the precursor in the carrier gas, and on the rapid expansion 
and quenching of the nucleated clusters or nanoparticles as they exit from the reactor 5. 
One disadvantage is the better versatility at temperatures above 600 °C, since many 
substrates are not thermally stable at these temperatures. Furthermore, there is the 
requirement of having chemical precursors with high vapor pressure which are often 
hazardous and at times extremely toxic, and the by-products of the reactions are also toxic 
and corrosive and must be neutralized, which can be costly 31. 
 
2.2.7 Solution combustion synthesis 
The solution combustion synthesis (SCS) is an exothermal redox reaction 
between an oxidizer (like metal nitrates) and a fuel (e.g., glycine, urea and citric acid). 
The advantages of the SCS are the resulting NPs with high specific surface area and high 
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reactivity, the use of inexpensive starting reagents, the self-sustained instantaneous 
reactions and the resultant high yield 32. 
 
 2.2.8 Plasma arc discharge  
The plasma arc discharge (PAD) is used to synthesize ultra-fine powders of 
magnetic oxides. In this method, the nanoparticles are immediately produced after the 
establishment of the arc between two electrodes. Some advantages are the ultra-fine MNP 
size with high purity and the high industrial scale production capacity. To control the 
desired size of the nanoparticles, some parameters are set such as arc discharge current, 
air chamber atmosphere and chamber pressure 33. The PAD method is used to synthesize 
MNPs coatings by carbon 5. 
 
2.2.9 Laser pyrolysis 
The synthesis of MNPs by the method of laser pyrolysis is promising, due to the 
efficiency of the process in the production of small sized particles and narrow size 
distribution (between 2-7 nm) 5,34,35. The laser pyrolysis is based on the resonant 
interaction between laser photons and at least one gaseous species – reactants or sensitizer 
34. This type of synthesis is used to prepare iron-based nanostructures 5. 
 
2.2.10 Co-precipitation 
With the co-precipitation method it is possible to synthesize oxides and ferrites 
by addition of a strong base on iron salts 5. The reaction can be represented by equation 
(1) where X can be Fe, Mn, Co, Cu, Mg, Zn and Ni. At the end of the precipitation it is 
expected that the solution pH stays between 8 and 14, with a stoichiometric ratio of 2:1 
(Fe2+/X2+) 5. 
 
X2+ + 2Fe3+ + 8OH¯ → XFe2O4 + 4H2O    (1) 
 
Magnetite nanoparticles (Fe3O4) are stable in environmental conditions, so they 
can be oxidized to maghemite (γ-Fe2O3) or dissolved in acidic medium. The size, shape 
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and composition of the MNPs  will depend on some factors such as the type of salts used 
(e.g., chlorides, sulfates and nitrates), the reaction temperature, the pH value, the type and 
strength of the base, the mixing rate, the ionic strength of the medium and the Fe2+/X2+ 
ratio 5. Hong et al (2008) used NH4OH instead of NaOH and they concluded that the 
NH4OH solution provides to NPs better crystallinity, smaller size and higher saturation 
magnetization 36. 
 
2.2.11 Reducing using plants extract 
Green synthesis or biosynthesis is a method that uses plant extract to produce 
MNPs. Several types of extracts have already been applied in this method, such as leaves, 
seeds and fruit extracts. Among the species already analyzed the following can be cited: 
Amaranthus dubius 37, Euphorbia milli, Datura innoxia, Calotropis procera, Tinospora 
cordifolia, Tridax procumbens and Cymbopogon citratus 7; Salvia officinalis 38; Hordeum 
vulgare and Rumex acetosa 39; Castanea sativa, Eucalyptus globulus, Ulex europaeus and 
Pinus pinaster 40; Citrullus lanatus 41 and green tea extract 42,43. 
In this type of synthesis the size and shape of NPs will depend on the 
characteristics of the extract, its localization in the plant, the reaction temperature, the 
stirring, the pH, and the biologic composition of plant (such as flavonoids, terpenoids, 
amino acids proteins, sugars) 44. In general , the size can vary between 2 and 40 nm 6,7,37–
42,45. 
Typically, the green synthesis is made only by adding the plant extract in a 
solution containing Fe (III) and/or Fe (II) at room temperature and stirring for a given  
time 37–40,45,46. However, to obtain NPs with the desired size the reaction temperature must 
be well controlled 7,41,42,44.  
Because it does not use many reagents and do not discard harmful components 
during the washing, this synthesis received the name of green synthesis or green route. 
Otherwise, there is the possibility of using a concentrated basic solution added to mixture 
of the iron solution with vegetal extract 6,8,47. So, it will be similar to the synthesis by co-
precipitation, but the NPs are coated by vegetal extract 6.  
In this thesis, it was chosen to use the methods of synthesis green routes and co-
precipitation to produce magnetite. Because of the possibility of using new plant extracts 
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for synthesis and environment friendly characteristic of the first one combined with the 
efficiency and practicality of the last one. 
 
2.3 Structure of nanoparticles 
The structure of nanoparticles can be very different from each other, due to the 
type of synthesis used, the composition and their purpose. According to the structure, 
nanoparticles can be classified as solid nanoparticles with uniform structure, hollow 
particles, Janus particles, core-shell (CS) particles, reverse bumpy balls particles and 
yolk-shell (YS) particles. Nanoparticles are generally found in the form of spheres, but 
they can be also cubic, spindle or rodlike 48. In Figure 1 is represented the structure 
classification of nanoparticles. 
 
Figure 1 - Transmission Electron Microscopy (TEM) images and schematic representations of the 
common types of nanoparticles: a) Solid nanoparticle, b) Hollow particle, c) Janus particle, d) Core-shell 
particle, e) Reverse bumpy balls and f) Yolk-shell particle 48. 
 
Usually, coated NPs are used because the coating decreases agglomeration and, 
in the case of biomedical applications, can improve the biocompatibility and decrease 
toxicity of the NPs. The coating can be polymeric or based on activated carbon, silica, 
gold, among other materials17. The coated structures more applied are core-shell and yolk-
shell. 
 
2.3.1 Core-shell 
Core-shell nanoparticles (CSNPs) are a class of particles that contains a core and 
a shell. The core and shell can be of different materials or both of the same material with 
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different structures. The core may be an aggregation of several small spheres or a single 
sphere. The shell structure can be a continuous layer or an attachment of smaller spheres 
onto a big core sphere, or aggregated core spheres. Complex core-shell structures may 
also be produced via incorporation of smaller spheres into the shell or with multiple shells. 
Both the core and the shell can be nonporous solids or having desirable porous structures. 
The size of the core particle, the thickness of the shell and the porosity are adjusted to be 
suitable to different types of applications 49.  
Normally, the CSNPs are synthesized by a process with two or more steps. The 
core particles are synthesized before and the coating is formed on the core particle using 
different methods, according with the type of core and coating materials, furthermore 
considering the morphology of the particles. The motivation in the preparation of core-
shell particles is to combine the desired properties of different materials and structures in 
order to offer simultaneous effect, to stabilize the active particles or to provide 
biocompatible properties 49. 
 
2.3.2 Yolk-shell 
In the last years, the yolk-shell nanoparticles (YSNPs) already received some 
different terminologies, including nanorattle, movable core/shell and core/shell with 
hollow interiors. The main difference between the CSNPs and YSNPs is the presence of 
void space derived from the sacrificial layer which gives rise to the multifunctional and 
other unique properties of YSNPs. Therefore, YSNPs are hybrid structures consisting of 
a movable core inside the hollow shell of the same or different materials 50. 
One of the advantages of the YS structure over the CS structure is that the first 
has the core surface unlocked compared to the second and, due to this, it provides more 
active locations and larger surface area. Moreover, the void space is suitable to 
accommodate the guest molecules and to provide space for the expansion of core NPs in 
many applications; the shell layer provides more active inner and outer surfaces, and the 
YSNPs can be synthesized even from a single material to enhance the specific surface 
area 50. 
These particles can be classified as spherical or non-spherical. The spherical 
particles are subdivided into single core-shell, multi-cores/single shell, single core/multi-
shells, multi-cores/shells and multi-shells or shell in shell. The non-spherical particles are 
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subdivided into partially non-spherical (where either the core or the shell of the YS has a 
non-spherical shape), and complete non-spherical (where both the core and the shell have 
a non-spherical shape) 50. 
The YSNPs synthesis often involves several steps including the fabrication of 
the core, growth of the shell, as well as various post-synthesis treatments such as core 
removal, functionalization of compartments and loading with cargo 48. In general, the 
synthesis of the YSNPs begins with the formation of the core (or yolk) of the structure, 
followed by coating with the desired material according to the application of the 
synthesized NPs 48,50.  
Graphene or reduced graphene oxide (rGO) has been used as shell of YS 
structures, integrating NPs of MnO2, Fe3O3, TiO2, Pt and Ag. The reduced graphene oxide 
favors a better dispersion of nanoparticles, improving their catalytic activity and 
durability 51. 
 
 
2.4 Applications 
Most applications of MNPs require features such as nanomaterials with specific 
sizes, shapes, surface characteristics and magnetic properties, chemical stability and good 
dispersion in liquid media. To achieve all this, it is necessary that the nanoparticles have 
functionalized surfaces 1. Thus, the surface of the MNPs must be modified with functional 
groups or suitable molecules, usually becoming a nanocomposite. Areas for applications 
of MNPs and magnetic nanocomposites are diverse, such as industrial, biochemical and 
biomedical 5.  
 
2.4.1 Industrial applications 
Among the many applications, MNPs can be applied to high density magnetic 
data storage devices, magnetic information storage, xerography, electronics, catalysis, 
magnetic inks, magnetic refrigeration and their systems 5. According to Teja & Koh 
(2009), the particles in data storage applications must have a stable, switchable magnetic 
state that could not be affected by temperature fluctuations. For optimum performance in 
recording, the particles should exhibit both high coercivity and high remanence, and they 
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should be uniformly small, and resistant to corrosion, friction and temperature changes. 
Due to its chemical and physical stability, maghemite is useful in recording and data 
storage, which may be cobalt-coated, in order to improve the coercivity and storage 
capacity. 
 
2.4.2 Biochemical applications 
2.4.2.1 Application in catalysis 
Catalysts based in MNPs have been widely used to improve the heterogeneous 
catalysis limitations. Such small and magnetically separable catalysts could combine the 
advantages of high dispersion and reactivity with easy separation. In this way, 
magnetically driven separations make the recovery of catalysts in a liquid-phase reaction 
much easier than using cross flow filtration and centrifugation, especially when the 
catalysts are in the nanometer size range 5. 
 
2.4.2.2 Environmental applications 
MNPs can be used as alternatives applied to the pumping and treatment of 
groundwater using permeable reactive barriers. Nanoparticles capable of reducing and 
stabilizing different types of compounds may be useful in this process, such as zero-valent 
iron NPs. An important property of iron nanoparticles is their enormous flexibility for in 
situ applications, but a major drawback is their sensitivity to oxidation in air and aqueous 
solutions. Environmental applications for MNPs include the ability of these materials to 
remove organic and inorganic pollutants 5. 
 
2.4.3 Biomedical applications 
2.4.3.1 Bioseparation  
In the biomedical area, separation of specific biological entities (e.g., DNAs, 
proteins and cells) from their native environment is often required for analysis. The on-
off nature of magnetization with and without an external magnetic field makes 
superparamagnetic colloids suitable for this situation, since they enable the transportation 
of biomaterials with a magnetic field. The separation processes of specific molecules are 
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used in almost all areas of bioscience and biotechnology. Various magnetic particles have 
been developed as magnetic carriers in separation processes, including purification and 
immunoassays. Separation techniques are extremely important in process engineering 52. 
 
2.4.3.2 Magnetic resonance imaging 
The use of nanoparticles of magnetite and maghemite has received considerable 
attention in the application as contrast agents by magnetic resonance imaging (MRI). This 
application require particles that exhibit superparamagnetic behavior at room temperature 
and that are stable in water at neutral pH and physiological conditions 1. 
According Ito et.al. (2005), paramagnetic ion chelates and ferromagnetic or 
superparamagnetic nanoparticles, with sizes ranging generally between 3 and 10 nm, 
were developed as MRI contrast agents and used in clinical diagnosis. Magnetic 
resonance imaging offers the advantage of a high spatial resolution of contrast differences 
between tissues. Due to the unique function of this imaging modality, it is necessary to 
develop effective contrast agents that enhance and amplify their diagnostic utility 52. 
 
2.4.3.3 Hyperthermia 
Magnetic hyperthermia (MH) is a clinical therapy used along with chemotherapy 
to achieve a synergistic effect to the combined treatment of cancer cells. The MH process 
is based on increasing the temperature of the target cells to 41-46 °C. At this temperature, 
the damage to normal tissue is reversible, while the tumor cells are irreversibly damaged. 
Recently, magnetic nanoparticles (mainly magnetite) have been used as heating agents 
for this treatment 1,4.  
In application to hyperthermia, magnetic nanoparticles, whose position and 
orientation can be controlled by a magnetic field, need an important requirement, which 
is the absorption of large losses under the reversal of repeated magnetization. The 
mobility of magnetic particles in ferrofluids is an important feature in the context of losses 
under repeated magnetization reversal. As the particles are free to rotate, the potential 
energy can be minimized in two ways: either the magnetic moment rotates within the 
particle until it is aligned with the field, or the particle rotates as a whole. Two different 
processes are involved to explain this, Néel and Brown relaxation, respectively. These 
relaxation movements cause the characteristic heating of MH 53. The efficiency of the 
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transformation of magnetic field energy by physical mechanisms strongly depends on the 
nature of the particles, such as particle size, state of agglomeration and viscosity of the 
medium 1,4. 
 
2.4.3.4 Drug delivery  
The controlled transportation and release of drugs aims to avoid wasting drugs 
and distributing them in unnecessary areas, also avoiding unwanted side effects. The NPs 
containing the drug are inserted into the bloodstream and guided with the aid of a 
magnetic field to the "target" where the drug is released. The release may occur due to 
enzymatic activity, or controlled by other specific factors, for example pH. The success 
of this method depends on the speed of the NPs in the bloodstream, the circulation time 
and the strength of the magnetic field in the region of interest 17. 
 
 
2.5 Drug delivery 
Controlled drug delivery systems are an alternative with the potential to 
overcome the challenges of administering anticancer drugs. The use of nanotechnology 
for this purpose has been promising, given the side effects of treatments such as 
chemotherapy and radiotherapy and the risks of surgeries for patients. The current 
drawback of cancer chemotherapy is that the drugs also affect healthy tissues, have low 
solubility in water and are poorly bioavailable. The NPs with diameters ranging from 10 
to 200 nm present promising pharmacokinetic features. Drug encapsulated NPs 
accumulate both passive and active mechanisms for extended and complete circulation 
periods, continuous drug discharge kinetics and recovery of tissues from tumor 54. In this 
context, the researches concerning nanocomposites stands out as to their ability to 
encapsulate therapeutic mediators and to coordinate their distribution to cancer cells 9. 
According to Singh & Lillard Jr.(2009), there is a great difficulty to efficiently 
control the release, which depends on the solubility of the drug, desorption of the surface-
bound or adsorbed drug, drug diffusion through the nanoparticle matrix, nanoparticle 
matrix erosion or degradation and the combination of erosion and diffusion processes 55. 
One of the alternatives to deliver the drug is through the changes on the pH of the medium, 
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since there is a difference between the pH of the normal tissues (pH 7.4), the extracellular 
environment of the tumor (pH 6.5) and the endosome and lysosome (pH 5.0) 56.  
NPs coated with polymers, metals or non-metals fail to release the drug 
controllably, while graphene oxide (GO) coated NPs have this advantage. The 
characteristics that allow this control and ensure GO excellent biocompatibility, 
physiological solubility and stability are related to the carbon domain with sp² 
hybridization, to the high specific surface area and to the enriched oxygen containing 
groups. In addition, -COOH (carboxylic) and GO-GO bonds facilitate conjugation with 
various systems, imparting GO with multi-functionalities and multi-modalities 57. 
The drug composed of doxorubicin hydrochloride (DOX) is an anthracycline 
antiblastic antibiotic isolated from cultures of Streptomyces peucetius var. caesius. The 
chemical structure of DOX is shown in Figure 2. It is soluble in water for injections and 
in physiological saline solution. This drug has been used successfully to produce 
regression in various neoplasms, such as breast cancer, lung, bladder, thyroid and ovary 
carcinoma, soft tissue sarcoma and bone sarcoma, Hodgkin's and non-Hodgkin's 
lymphomas, neuroblastoma, Wilms' tumor, acute lymphoblastic leukemia and acute 
myeloblastic leukemia 58.  
The use of DOX is clinically limited due to the phenomena of cell resistance, 
strong side effects and a dose dependent cardiotoxicity. Drug targeting by binding DOX 
to SPION could overcome these limitations. DOX is bound to the nanoparticle surface 
through a pre-formed DOX–Fe2+ complex. The DOX-loaded SPION presents interesting 
properties in terms of drug loading and biological activity 10,11. 
 
Figure 2 – Chemical structure of Doxorubicin 10. 
 
Researches seek to improve this technique, concentrating on an efficient and 
specific version, minimizing the side effects that can be caused. The importance of 
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development and improvement for treatments of cancer is related to the cure or 
considerable length of life of patients. This premise is based on the world scenario, 
according to the World Health Organization (WHO), which reported that in 2012 there 
were about 14 million new cases of cancer, with forecast of 70% increase in new cases 
for the next two decades. In addition, this disease accounted for about 8.8 million deaths 
in 2015 59. Therefore, this report reveals the importance of improving the efficiency of 
treatments for cancer.
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3.1 Materials 
For magnetic core synthesis were used solution with iron (III) chloride 6-hydrate 
pure (Applichem-Panreac, Germany) and iron (II) chloride tetrahydrate (Sigma-Aldrich, 
Germany) as iron source for magnetite formation. Ammonium hydroxide solution 1 molar 
(from ammonia solution 25%, Applichem-Panreac, Germany) was used to enable co-
precipitation of nanoparticles. In the early stages of the coating reaction, the CYSMNPs 
were dispersed in ethanol absolute (Fisher Scientific, U.K.) and distilled water and the 
hydrolysis and polymerisation of tetraethyl ortosilicate (TEOS, Fluka Cheika, Germany) 
was favoured. Subsequently, as the reaction progressed and the TEOS hydrolysis and 
polymerisation processes neared completion, the polymerisation of resorcinol (Fisher 
Scientific, U.K.) and formaldehyde (37-38% p/p, Panreac, Spain) became the 
predominant process, resulting in the formation of a phenolic resin polymer layer9. To 
remove the Silica was used sodium hydroxide solution (Fisher Scientific, U.K.). The 
phosphate buffer solutions to drug loading and release were prepared with phosphate 
buffer solution (PBS, Fisher Scientific, USA), potassium dihydrogen phosphate (V.P., 
Portugal), disodium hydrogen phosphate 12-hydrate (Pronalab, Portugal), and sodium 
dihydrogen phosphate hydrate (Pronalab, Portugal). 
 
 
3.2 Process fluxogram  
For a better understanding of the process, the following fluxogram represents the 
steps of the methodology used, Figure 3. Those steps will be described in detail in 
sequence. 
 
 
Figure 3 – Fluxogram of the process. 
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3.3 Magnetic core synthesis 
The magnetic core was synthesized according to the methodology described by 
Awwad & Salem (2012), i.e., using a solution of Fe (II) and Fe (III). Approximately 0.53 
g of FeCl2.4H2O  and 1.11 g of FeCl3.6H2O (1:2 molar ratio) were dissolved in 100 mL 
of distilled water. The vessel containing this solution was placed in an oil bath on a 
magnetic stirring plate (IKA® C-MAG HS 7, Figure I - Annex A) with temperature 
control until 30 ºC (IKA® ETS-DS, Figure I - Annex A), and at this temperature, 5 mL of 
plant extract were added 6. The extract concentration was 100 times higher than the EC 
50 RP concentration, i.e. the extract concentration calculated from the method of Oyaizu 
(1986) to determine reducing power 60,61. Different plant hydromethanolic extracts with 
high reducing power were investigated in the synthesis of magnetic cores, such as Rubus 
ulmifolius Schott flowers (EC 50 PR 40 µg.mL-1), Tamus communis L. shoots (EC 50 PR 
68 µg.mL-1) and Crateagus monogyna Jacq. flowers (EC 50 PR 19 µg.mL-1). After 5 
minutes, 30 mL of ammonium hydroxide were added dropwise to the mixture using a 
peristaltic pump ISM 845, ISMATEC (Figure II - Annex A), Figure 4. The solution 
remained in stirring during 1 hour at 30 ºC. A representation of this synthesis 
methodology can be observed in Figure 5.  
 
 
Figure 4 - Dropwise addition of ammonium hydroxide solution during the process of synthesis of the 
magnetic core. 
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Figure 5  - Magnetic core synthesis methodology. 
 
The solution was washed with distilled water by centrifugation at 600 rpm during 
5 minutes in MPW-260R centrifuge, MPW Med. Instruments (Figure III - Annex A). The 
washing process was repeated 7 times. Finally, the last washing was done with ethanol 
and then the MNPs were dried at 60 ºC in a drying oven, Binder FD 115 (Figure IV - 
Annex A).  
Subsequently, the magnetic core was characterized by X-ray diffraction (XRD) 
and Transmission Electron Microscopy (TEM) in order to perform phase identification 
and determine the crystalline structure and the total core size. XRD analysis was 
performed in a PANalytical X’Pert MPD equipped with a X’Celerator detector and 
secondary monochromator (Cu Kα λ= 0.154 nm; data recorded at a 0.017° step size). The 
composition of magnetite present were identified using HighScore software and 
Crystallography Open Database. Rietveld refinement of the XRD diffraction patterns was 
performed using PowderCell software allowing phase quantification. Crystallite sizes 
were determined by the Williamson-Hall method 62. TEM was performed in a LEO 906E 
instrument operating at 120 kV, equipped with a 4 Mpixel 28 × 28 mm CCD camera from 
TRS 62. ImageJ software was used to estimate the size of the magnetic nanoparticles. 
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3.2 Coating 
The protocol proposed by Liu et. al. (2014) was used to produce the carbon-based 
coating. At the first step, 0.25 g of magnetic nanoparticles synthesized by the method 
previously described were suspended in 150 mL of ethanol and 50 mL of distilled water, 
which was ultrasonicated for 45 minutes, in Ultrasons-H, P-Selecta (Figure V - Annex 
A). That solution was then poured into a 500 mL round bottom flask with 0.05 g of 
resorcinol and 0.7 mL of ammonia solution (25%). That mixture remained in stirring for 
1 h at 30 ºC in an oil bath on a magnetic stirring plate with temperature control. Then, 
0.075 mL of formaldehyde solution (37-40%) and 0.100 mL of tetraethyl orthosilicate 
(TEOS) solution were added dropwise and the mixture stirred for 6 h at the same 
temperature. After that, the mixture was heated at 80 ºC for 8 h under stirring. The process 
was repeated with different reagent quantities, such as 0.1 g of resorcinol, 1.4 mL of 
ammonia solution (25%), 0.15 mL of formaldehyde solution (37-40%) and 0.205 mL of 
TEOS solution. The resultant solid was washed 7 times with distilled water by 
centrifugation at 600 rpm for 5 minutes. Finally, the last washing was done with ethanol 
absolute, then the MNPs were dried at 60ºC in the drying oven. The resultant NPs were 
denoted Fe3O4@polymer 
9.  
At the second step of the coating process, the Fe3O4@polymer sample was 
carbonized under a N2 atmosphere in a vertical tubular furnace (ROS 50/250/12, 
Thermoconcept, Figure VI - Annex A). The carbonization occurred to 600 ºC at a heating 
rate of 1 ºC.min-1 and the temperature was maintained at 600 ºC for 3 h. The resultant 
NPs were denoted Fe3O4@SiO2.C. Finally, the Fe3O4@SiO2.C nanoparticles were etched 
under stirring with sodium hydroxide solution 10 mol.L-1 for 24 h at room temperature 
and the product was washed by centrifugation with distilled water several times, until 
reaching pH 7. After that, it was washed with ethanol and dried at 60 ºC in a drying oven. 
The obtained sample was Fe3O4@void@C 
9. The coated nanoparticles were characterized 
by TEM to determine the NPs total size and the carbon material thickness. 
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3.3 Functionalization 
The functionalization of the CYSMNPs was performed by acid treatment. The 
coating product was added to nitric acid solution 1 mol.L-1 in the ratio 5 mg:1 mL and 
maintained at 60 ºC for 1.5 h under stirring in oil bath on a magnetic stirring plate with 
temperature control. The process was repeated for other samples, but with time of reaction 
of 3 and 6 hours to compare the results. The product of the reaction was washed by 
centrifugation at 600 rpm during 5 minutes. The process was repeated several times with 
distilled water, and one more time with ethanol absolute, then the MNPs were dried at 60 
ºC in a drying oven.  
The samples were combined with KBr and compacted into pellets using a press in 
order to do analysis of spectra on Fourier transform infrared spectrometer (FT-IR). The 
analysis was performed for both non-functionalized and functionalized CYSMNPs in a 
ABB Inc. MB 3000 with a resolution of 16 cm-1 and a spectrum from 550 to 4000 cm-1. 
The data was processed using Horizon MB 3.4 software allowing absorption bands 
identification. 
The point of zero charge (pHpzc) of the functionalized CYSMNPs were determined 
using NaCl solutions 0.01 M. Initially, 0.05 g of functionalized and non-functionalized 
CYSMNPs were placed in two different erlenmeyers and 20 mL of NaCl 0.01 M with pH 
initial of 7.22 (pHi) were added in each erlenmeyer. After 48 hours in a IKA
® KS 130 
basic orbital shaker (Figure VII - Annex A), the mixtures were centrifuged 2 times at 
6000 rpm during 5 minutes and the supernatant was used to measure the pH after their 
equilibration (pHf). Subsequently, 0.05 g of non-functionalized CYSMNPs with 20 mL 
of NaCl 0.01 M  pHi 10.00 were placed in an erlenmeyer and 0.05 g of functionalized 
CYSMNPs with 20 mL of NaCl 0.01 M pHi 1.74 were placed in another erlenmeyer. The 
mixtures stayed in the orbital shaker during 48 hours and the centrifugation process was 
repeated, as well the measurement of pHf. The comparison between pHi and pHf makes 
possible to establish the pHpzc and to know the effect of functionalization in the 
nanocomposites. 
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3.4 Drug Loading and Release 
Phosphate buffer solutions (PBS) with different pH were used for the tests with 
the drug. These solutions were prepared as following: a) PBS pH 4.5: 3.40 g of 
dihydrogen potassium phosphate was diluted in 0.5 L of distilled water; b) PBS pH 6.0: 
49.2 mL of Na2HPO4.12H2O 0.2 M solution was mixed with 350.8 mL of NaH2PO4.H2O 
0.2 M solution; c) PBS pH 7.4: the standard solution of PBS was diluted 10 times; d) PBS 
pH 8.0: 331.5 mL of Na2HPO4.12H2O 0.2 M solution was mixed with 18.5 mL of 0.2 M 
NaH2PO4.H2O solution. 
First, a test was performed to analyze drug loading capacity (DLC) and drug 
loading efficiency (DLE) in different drug ratios for CYSMNPs. Solutions with the 
following concentrations of DOX were prepared in distilled water in 10 mL volumetric 
flasks: 20 µg.mL-1, 50 µg.mL-1, 100 µg.mL-1, 200 µg.mL-1, 400 µg.mL-1 and  
600 µg.mL-1. The aspect of the DOX solutions can be observed in Figure 6. 1 mL of a 
DOX solution and 1 mL of CYSMNPs functionalized during 3 h were added in glass 
tubes, each concentration of DOX solution being analyzed in triplicate and the flasks 
protected from light. The samples stayed in the orbital shaker during 24 hours and after 
this time each sample was centrifuged 2 times in eppendorfs of 3 mL at 8000 rpm during 
5 minutes. The supernatant was measured at 480 nm in a T70 UV-VIS spectrometer, PG 
Instruments Ltd. (Figure VIII - Annex A), to identify the concentration of the DOX that 
was loaded in each solution. The loading was expressed in terms of DLE and DLC. That 
test was repeated using DOX solutions in phosphate buffer solution (PBS) pH 7.4. 
 
Figure 6 – Dox solutions of concentration 20 µg.mL-1, 50 µg.mL-1, 100 µg.mL-1, 200 µg.mL-1, 400 
µg.mL-1 and 600 µg.mL-1, from left to right respectively. 
 
To compare in which medium the drug load would be higher, different solutions 
were prepared with 5 mg of functionalized CYSMNPs during 3 and 6 h for a volume of 
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5 mL in different conditions: PBS pH 6.0, PBS pH 7.4 and PBS pH 8.0. Those solutions 
were mixed with 5 mL of Doxorubicin solution with a concentration of 1 mg.mL-1 also 
prepared in PBS pH 6.0, PBS pH 7.4 and PBS pH 8.0. Those mixtures were placed in the 
orbital shaker for 24 h. Then, the samples were centrifuged and the supernatant was 
measured by UV-Vis spectrophotometry at 480 nm to determine the drug loading 
capacity. Subsequently, the solution which had better result was repeated in larger scale 
with 20 mg of functionalized CYSMNPs and 20 mg of Doxorubicin in 20 mL of solution, 
and after of the centrifugation, that sample was freeze-dried for the release test. 
The release test was made in duplicate for different solutions: PBS pH 4.5, PBS 
pH 6.0 and PBS pH 7.4. Between 1 and 2 mg of freeze-dried CYSMNPs-DOX were 
weighed and 10 mL of each solution were added in each flask. The flasks were placed in 
the orbital shaker and after 30 minutes the mixture was centrifuged to separate 
CYSMNPs-DOX of the supernatant. The CYSMNPs-DOX returned for the flask, where 
10 mL of the same solution were added and the flasks returned to the orbital shaker, while 
supernatant was measured by UV-Vis spectrophotometry at 480 nm to identify the 
concentration of the DOX that was released in each solution. This process of 
centrifugation and analysis of the supernatant was repeated in times of 1, 2, 4, 6, 24 and 
48 h. From the data collected, a curve of the concentration released over time was plotted 
to analyze the difference of the drug release at different pH.
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4.1 Synthesis of iron oxide nanoparticles 
The synthesis of the magnetic cores were performed with the three plants extracts, 
Rubus ulmifolius Schott flowers, Tamus communis L. shoots and Crateagus monogyna 
Jacq. Flowers, which were compared among themselves. The three types of core were 
found to be very magnetic (Figure 7-a), to have black color and resulted in similar yields, 
approximately 516 mg, 501 mg and 416 mg, respectively (Figure 7-b). But visibly, the 
more stable magnetic core in distilled water was that synthesized with Rubus ulmifolius 
Schott flowers extract, as shown in Figure 8. 
 
Figure 7 – a) Magnetic core; b) Magnetic cores synthesized with extracts of Rubus ulmifolius Schott 
flowers, Tamus communis L. shoots and Crateagus monogyna Jacq. flowers, from left to right 
respectively. 
 
Figure 8 - Stability of the magnetic cores in distilled water with extracts of Rubus ulmifolius Schott 
flowers, Tamus communis L. shoots and Crateagus monogyna Jacq. flowers, from left to right 
respectively. 
 
The XRD spectrum of the magnetic core nanoparticles are presented in Figure 9. 
The peaks at 30.62º, 35.75º, 43.37º, 53.70º, 57.38º, 63.06º and 74.37º are attributed to the 
crystal planes of the magnetic cores at 220, 311, 400, 422, 511, 440 and 533, respectively. 
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The relative intensity of the diffraction peaks match with the standard XRD data for 
magnetite (JCPDS no. 19-0629). Therefore, the investigation of phase by XRD confirms 
the crystal structure of the 3 cores synthesized as that of magnetite. Moreover, the core 
with Rubus ulmifolius Schott flowers extract has particle size of 13.5 ± 1 nm, while the 
cores with Tamus communis L. shoots and Crateagus monogyna Jacq. flowers extract 
have particle sizes of 12.3 ± 0.6 nm and 12.8 ± 0.5 nm, respectively. TEM image 
presented in Figure 10 shows magnetite core synthesized with Rubus ulmifolius Schott 
flowers extract with average size of 13.42 ± 3.51 nm. The observed agglomeration is 
related to the magnetic characteristics of the sample. 
 
 
Figure 9 - XRD patterns of the magnetic cores synthesized with Rubus ulmifolius Schott flowers, Tamus 
communis L. shoots and Crateagus monogyna Jacq. flowers extracts. 
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Figure 10 - TEM image of the magnetite core synthesized with Rubus ulmifolius Schott flowers extract. 
 
Because of the best stability in distilled water of the magnetic core produced with 
the Rubus ulmifolius Schott flowers extract, this was chosen to continue the experiments. 
That species, known as wild blackberry, is regarded as an interesting medicinal plant and 
considered to be anti-catarrhal, antiseptic, diuretic, anti-inflammatory, antioxidant, 
astringent and antispasmodic. In its extract, twenty-four phenolic compounds can be 
identified, such as phenolic acid derivatives (di- and caffeoylquinic, p-coumaroylquinic, 
feruloylquinic acids and ellagic acid), flavonoids (quercetin and kaempferol derivatives 
and catechin) and hydrolysable tannins (lambertianin, sanguiin and four di-
hexahydroxydiphenol (HHDP)- galloyl glucose isomers) 60. For the green routes 
synthesis, the flavonoids are probably involved in the stages of initiation of nanoparticle 
formation and further aggregation, in addition to the bioreduction stage, because they 
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contain various functional groups capable of nanoparticle formation 44. Besides the 
composition and reducing power of the extract, the methodology adopted uses ammonium 
hydroxide to perform the synthesis of the magnetite core by the chemical precipitation 
method. 
 
 
4.2 Carbon-based coating 
The coating processes of the magnetite core were identified according to the 
quantities of reagents used, as follows: a) 0.05 g of resorcinol, 0.7 mL of ammonia 
solution (25%), 0.075 mL of formaldehyde solution (37-40%) and 0.100 mL of TEOS 
solution; and b) 0.1 g of resorcinol, 1.4 mL of ammonia solution (25%), 0.15 mL of 
formaldehyde solution (37-40%) and 0.205 mL of TEOS solution. It was found that the 
coating process ‘a’ was not sufficient to cover the magnetite core. In addition, during this 
process, the magnetite nanoparticle was oxidized and the resulting solid had a dark red 
appearance. However, the coating process ‘b’ resulted in coated nanoparticles of dark 
black color and preserved the initial magnetic characteristics. Both samples were 
analyzed by TEM (Figure 11), which made possible to know the size of the coated 
nanoparticles. The coating processes ‘a’ and ‘b’ resulted in particles with average sizes 
of 12.99 ± 3.29 nm and 20.16 ± 8.68 nm, respectively.  
When the objective is to have a material for drug delivery application, there is a 
need for better therapeutic materials that have good drug solubility, an ability to reduce 
systemic toxicity through specific-tumor targeting and rapid clearance63. Carbon-based 
nanomaterials are important due to their unique combination of chemical and physical 
properties, such as thermal and electrical conductivity, high mechanical strength and 
optical properties, then higher chemical and thermal stability, larger surface area, 
biocompatibility and easier functionalization. Due to those advantageous properties they 
are also actively investigated in several areas of biomedical engineering 63,64. 
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Figure 11 - TEM images of the samples resulted from the coating processes ‘a’ and ‘b’, from left to right 
respectively. 
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According to Liu et. al. (2014), the magnetic mesoporous carbon hollow 
nanoparticles can be used as drug delivery carriers and diagnostic agents for cancer, due 
to the large volume in the cavity between the yolk and the shell that provides sufficient 
space for the loading of drugs. Moreover, the use of magnetic nanocomposites with a YS 
mesoporous structure can be an effective solution to CS structure problem; since the CS 
magnetic properties are sometimes restrained to a specific range because the core 
materials are easily and compactly encapsulated in the shell material, while YS materials 
with interstitial spaces between the mesoporous shells and the magnetic cores can have 
movable magnetic nanoparticles packed in the mesoporous hollow shells 9. However, it 
has been confirmed that the nanoparticles coated by process 'b' have sufficient space for 
higher drug loading capacity, as will be seen below. 
 
 
4.3 The effects of the functionalization 
The functionalization with nitric acid added carboxylic acid groups (-COOH) to 
the CYSMNPs structures, increasing the acidity of the nanocomposites. The point of zero 
charge (pHpzc) was investigated to compare the acidity of the material before and after 
functionalization, with the measures of pHi and pHf the graphs 12-a and 12-b were 
constructed, Figure 12.  
From the equation of the line obtained by the graph, knowing that it represents the 
pHf and that the zero load point is found by means of the chemical equilibrium, when we 
consider pHi=pHf, the pHpzc value is found using the following equations: 
𝑦 = 0,2878𝑥 + 6,5823    (a) 
𝑦 = 0,292𝑥 + 1,352     (b) 
If pHi=pHf, so y=x. These values of x and y correspond to 9.24 and 1.91 for the 
non-functionalized (12-a) and functionalized (12-b) CYSMNPs, respectively. Those 
results showed that functionalization made the CYSMNPs more acidic.  
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Figure 12 – Results of measurement of pHi and pHf resulting from the pHpzc test of a) non-
functionalized CYSMNPs; and b) functionalized CYSMNPs. 
 
In addition, the spectral analysis in the Fourier transform infrared spectrometer 
(FT-IR), Figure 13, shows the comparison of the spectra of the nanocomposites before 
and after functionalization. The presence of magnetite in non-functionalized CYMNPs is 
noticed in the absorption bands of 564 cm-1, 1628 cm-1 and 3433 cm-1. The first band 
corresponds to the vibration of the Fe–O bond, and the latter two can be attributed to the 
bending and stretching vibrations of the surface –OH groups present in Fe3O4 65. 
The absorption bands at 1380 cm-1, 1458 cm-1, 1627 cm-1, 2923 cm-1 and  
3433 cm-1 represent the C-O, O-H, C=O, C-H and O-H bonds respectively, which indicate 
that there are carboxylic acid groups in the samples. In the functionalized sample the 
increase in the absorption band in the region 1000-1400 cm-1 can be attributed to the C-
O stretching frequencies of the -COOH groups 65. In addition, the increase in the intensity 
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of the absorption bands at 1380 and 1627 cm-1 represents the increase in the C-O and 
C=O bonds of the carboxylic acid groups 66. However, this indicates the increase of the 
carboxyls, which are responsible for making the nanocomposites more acidic. The 
presence of carboxyls in nanocomposites can improve colloidal stability and 
monodispersibility in aqueous solutions 66.  
 
 
Figure 13 - Absorption bands of functionalized and non-functionalized CYSMNPs. 
 
4.4 Capacity and efficiency of drug loading 
Initially, the DLC (µg.µg-1) and DLE (%) were studied for solutions with different 
concentrations of DOX in 2 solution media (distilled water and PBS pH 7.4) using 
functionalized CYSMNPs during 3 hours.  
 
𝐷𝐿𝐶 =
𝐶𝐷𝑂𝑋−𝐶𝑌𝑆𝑀𝑁𝑃𝑠
𝐶𝐶𝑌𝑆𝑀𝑁𝑃𝑠
     (1) 
 
𝐷𝐿𝐸(%) =
𝐶0𝐷𝑂𝑋−𝐶𝑓𝐷𝑂𝑋
𝐶0𝐷𝑂𝑋
∗ 100        (2) 
Where, CDOX-CYSMNPs is concentration of Doxorubicin loaded in the CYSMNPs, 
CCYSMNPs is concentration of CYSMNPs, C0DOX is initial concentration of DOX before 
loading, Cf DOX is final concentration of DOX in supernatant after loading. 
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The results of this test can be observed in Figure 14. The DLC and DLE maximum 
were 0.193 µg.µg-1 (300 µgDOX.mL
-1) and 97.9 % (50 µgDOX.mL
-1) for solutions in 
distilled water, and 0.514 µg.µg-1 (300 µgDOX.mL
-1) and 98.4% (100 µgDOX.mL
-1) for 
solutions in PBS pH 7.4. Therefore, PBS pH 7.4 is better than distilled water to be used 
as the loading medium. In addition to the electrolytes present in distilled water that do not 
allow its pH to remain constant, the solution whose pH is closest to pKa of the drug 
(Doxorubicin, pKa 8.3) will have better absorption of it. 
 
Figure 14 – Results of drug loading test in distilled water and PBS pH 7.4. a) Drug loading capacity; b) 
Drug loading efficiency. 
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After this initial test of drug loading, a test with CYSMNPs functionalized for 3 
and 6 h was compared in other PBS solutions with different pH. The ratio of drug and 
CYSMNPs used for this comparison test was 1:1 (w/w). Figure 15 shows the solutions 
prepared that were used in this test, and Figure 16 shows the supernatants of those samples 
after centrifugation and separation of the nanoparticles. The DLC and DLE values are 
given in Table 1. 
 
Figure 15 - a) Functionalized CYSMNP in solutions of pH 6.0, pH 7.4 and pH 8.0, from left to right 
respectively; b) Doxorubicin in solutions of pH 6.0, pH 7.4 and pH 8.0, from left to right respectively.  
 
Figure 16 - The samples of supernatants used to analyze drug loading efficiency and drug loading 
capacity in different pH by UV-Vis at 480 nm (The samples above correspond to pH 6.0, pH 7.4 and pH 
8.0, from left to right respectively). 
 
Table 1 – Results of drug loading test with different functionalization times in different solutions. 
Solutions Functionalization 3 h Functionalization 6 h 
 DLC (µg.µg-1) DLE (%) DLC (µg.µg-1) DLE (%) 
PBS pH 6.0 0.934 ± 0.007 93.4 ± 0.7 0.943 ± 0.005 94.3 ± 0.5 
PBS pH 7.4 0.955 ± 0.004 95.5 ± 0.4 0.981 ± 0.001 98.1 ± 0.1 
PBS pH 8.0 0.996 ± 0.000 99.6 ± 0.0 0.996 ± 0.001 99.6 ± 0.1 
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The loading difference at different pH can be explained mainly due to the solution 
whose pH is approximately the pKa of the drug (Doxorubicin, pKa 8.3). As explained 
previously, this allows greater electrostatic affinity between the drug (positively charged) 
and the functionalized CYSMNPs (negatively charged), and consequently a higher drug 
loading. 
Although stability in aqueous solution had increased with the functionalization 
during 6 h, it also affected the magnetic characteristics of CYSMNPs. Therefore, and also 
because these nanoparticles did not present significant differences in drug loading, it was 
decided to continue the experiments only with the functionalization of 3 h. In addition, 
functionalizing for 3 h saves time and has a better recovery of the material during the 
washings of the solids resulting from the reaction. Then, the two best results for 
CYSMNPs functionalized during 3 h (PBS 7.4 and PBS 8.0) were repeated with more 
quantity, 20 mg of functionalized CYSMNPs, to prepare samples for drug release. The 
results are shown in Table 2. 
 
Table 2 - Results of drug loading to prepare samples for drug release. 
Solutions Functionalization 3 h 
 DLC (µg.µg-1) DLE (%) 
PBS pH 7.4 0.914 91.4 
PBS pH 8.0 0.993 99.3 
 
It is noteworthy that increasing the mass for the same process, the values of DLC 
and DLE decreased. Even though the result for the PBS solution at pH 8.0 was better, 
during the process of preparing the solutions for loading, it was observed that in this 
medium the drug had poor solubility. Therefore, even though the solution of pH 7.4 did 
not have the best results, they would be more reliable, besides having a better drug 
solubility. So, CYSMNPs-DOX loaded at pH 7.4 was chosen to perform the release tests. 
 
 
4.5 pH dependent release 
The pH dependent release is very important due to the difference between the pH 
of the normal tissues (pH 7.4), the extracellular environment of the tumor (pH 6.5) and 
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the endosome and lysosome (pH 5.0) 56. Therefore, if more drug is released in the more 
acidic environment, the better will be the treatment of the tumor and lower will be the 
side effects and damage to the healthy cells. The release test previously described 
presented higher drug release in acidic medium, as expected. The cumulative drug release 
(%) of the amount of drug retained in nanocomposites were 32.35%, 27.18% and 11.95% 
in PBS solutions with pH 4.5, pH 6.0 and pH 7.5, respectively, Figure 17. These results 
can be expressed in cumulative concentration 52.01 µg.ml-1, 37.26 µg.ml-1 and 16.39 
µg.ml-1, which represent in weight of DOX the quantities of 520.16 µg, 372.56 µg and 
163.86 µg in PBS solutions with pH 4.5, pH 6.0 and pH 7.5, respectively. The drug release 
over time is represented in Figure 18. 
 
 
Figure 17 - Drug release in percentage of DOX over time. 
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Figure 18 – Drug release in weight of DOX over time. 
 
 
 
The drug release has shown to have a dependence with the pH of the targeting 
cells with acid pH. Thus, pH controlled drug release would be a viable application to the 
synthesized material. The CYSMNs would be conducted to the target with a magnetic 
field and the pH of the environment would act on the release of the drug. The disadvantage 
is that much weight of the drug was retained in the CYSMNPs, but the amount released 
is still relevant to the application for which it is proposed. Therefore, this research 
demonstrates the outstanding ability to use the developed and optimized green 
CYSMNPs, as super-drug nanocarriers with great ability to load high content of the 
anticancer drug Doxorubicin. 
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5.1 Conclusions 
Based on the premise of optimizing yolk-shell magnetic nanocomposites for the 
treatment of cancer, this thesis was concluded aiming to obtain the release of higher 
amount of drug in the more acidic medium, which corresponds to the medium of cancer 
cells. Thus, considering all the optimizations made during the synthesis, coating, 
functionalization and loading and release of the drug, the final release result obtained was 
approximately 20% higher in solution with equivalent pH to the cancer cells than in an in 
solution with equivalent pH to normal cells. A considerable disadvantage was the large 
amount of drug retained in the material, which still needs an optimization to improve the 
drug exploitation and to obtain better yield of release. Therefore, in this study, the 
synthesized nanocomposites CYSMNPs were efficient and intelligent for application in 
targeted drug delivery.  
 
 
5.2 Future research 
A hyperthermia study will be conducted to apply these nanocomposites 
synergistically for drug administration and hyperthermia, thinking about a more effective 
treatment of cancer. In addition, drug release needs to be improved so that fewer drugs 
are maintained in the nanocomposites. There is interest in performing other tests such as 
the zeta potential to determine the surface charge of nanoparticles in solution (colloids), 
among others tests and optimization to assess the viability of applying this material both 
for its capacity and harmlessness. 
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Figures I to VIII show the equipment used during the experiments. 
 
 
Figure I - Magnetic stirring plate IKA® C-MAG HS 7 with temperature control IKA® ETS-D5. 
 
 
Figure II - Peristaltic pump ISM 845, ISMATEC. 
 
 
Figure III - Centrifugal MPW-260R, MPW Med. Instruments. 
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Figure IV - Drying oven FD 115, Binder. 
 
 
Figure V - Ultrasons-H, P-Selecta. 
 
 
Figure VI - Vertical tubular furnace ROS 50/250/12, Thermoconcept. 
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Figure VII - Orbital shaker IKA® KS 130 basic. 
 
 
Figure VIII - T70 UV-VIS spectrophotometer, PG Instruments Ltd. 
